PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.76%
Cash & equivalents declining -19.76% while Biotechnology shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-19.76%
Below half the Biotechnology median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.43%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-20.12%
Below half the Biotechnology median of 0.00%. Jim Chanos would question if the company faces working capital strain.
13.37%
PP&E growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.42%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Below half the Biotechnology median of 0.00%. Jim Chanos might see potential stagnation or distress vs. peers.
-6.57%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-17.63%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.63%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
0.13%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2.90%
Near Biotechnology median of -2.79%. Charlie Munger sees typical yoy changes in retained earnings.
-5.63%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
Below half Biotechnology median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-19.74%
Below half Biotechnology median of 0.00%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.76%
Above 1.5x Biotechnology median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.